Cyclerion Therapeutics, Inc.
CYCN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | 0.03 | 0.03 |
| FCF Yield | -53.44% | -271.25% | -142.45% | -54.25% |
| EV / EBITDA | -1.34 | -0.02 | -0.83 | -0.25 |
| Quality | ||||
| ROIC | -40.99% | -85.46% | -421.70% | -114.40% |
| Gross Margin | 100.00% | 0.00% | 78.11% | 85.78% |
| Cash Conversion Ratio | 1.42 | 1.69 | 2.23 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | 88.84% | -100.00% | -49.43% | -9.69% |
| Free Cash Flow Growth | 79.60% | 47.69% | -11.19% | 50.65% |
| Safety | ||||
| Net Debt / EBITDA | 0.89 | 0.60 | 0.74 | 1.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -3,449.69 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.08 | 0.51 |
| Cash Conversion Cycle | 101.47 | 0.00 | -12,039.33 | -684.98 |